Vertex Pharmaceuticals CEO talks AI
New England Council member, Vertex Pharmaceuticals, recently participated in a discussion on artificial intelligence and the future of drug discovery at the Boston College Chief Executives Club. Vertex CEO Reshma Kewalramani joined Nasdaq CEO Adena Friedman for a conversation about the potential of AI in healthcare innovation and the challenges ahead for the biotech public markets.
During the event, Kewalramani shared that she initially was skeptical of AI’s capabilities in drug development; her view has recently shifted as technology has expanded. Rather than replacing scientists, AI is helping streamline processes, such as preparing regulatory filings, which typically take 6 to 9 months to complete. Friedman noted that we are “at the very beginning of what’s possible” when it comes to using AI in innovative industries.
“I’ve changed my mind. While we don’t have a computer in the basement spitting out medicines, AI is helping us focus more of our energy on scientific discovery and less on administrative work,” said Kewalramani.
The New England Council applauds Vertex Pharmaceuticals for its continued leadership in life sciences innovation and looks forward to learning more about the future of artificial intelligence and healthcare.
Read more in the Boston Business Journal and the Boston Globe.